Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.81 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
| ▸ | VDR | P11473 | 1/20 | 0.80 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 5/20 | 0.68 |
| ▸ | CA2 | P00918 | 5/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycodeoxycholate SCHEMBL27652429 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL13851639 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL26088647 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL24841 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL23704979 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL23704978 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL4301 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL23710381 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL20955852 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A | |
| Glycodeoxycholate SCHEMBL24840 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4SLC10A2TBXA2RPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427289-B1 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | IONIS PHARMACEUTICALS INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9175027-B2 | Polymer-carbohydrate-lipid conjugates | LIPOSEUTICALS, INC. | 2015-11-03 | — | — | US | disclosed |
| US-8946178-B2 | Compositions and methods for treatment of pouchitis | ISIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8691785-B2 | Compositions and methods for non-parenteral delivery of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130274309-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-8377897-B2 | Compositions and methods for non-parenteral delivery of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120270920-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF POUCHITIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | BIOZONE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1427289-A2 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | ISIS Pharmaceuticals, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6747014-B2 | FOR THERAPY OF INFLAMMATORY BOWEL DISORDER | ISIS PHARMACEUTICALS, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030124196-A1 | Pulsatile release compositions and methods for enhanced intestinal drug absorption | ISIS PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030083286-A1 | Bioadhesive compositions and methods for enhanced intestinal drug absorption | ISIS PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003017940-A2 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | ISIS PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030040497-A1 | Compositions and methods for non-parenteral delivery of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | LIPA, CETP, DGAT2 | GPBAR1 31/4885NR1H4 11/4885SLC10A2 17/4885 |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | GPBAR1 1670/4885NR1H4 950/4885SLC10A2 354/4885 |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | GPBAR1 1670/4885NR1H4 950/4885SLC10A2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.